Rituximab-pvvr is not an independent predictor for infusion reactions in a cohort given rituximab-pvvr or rituximab: A single-center retrospective study

Abstract

Get full access to this article

View all access options for this article.

References

Jung

Kang

Lee

, et al. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. Oncology 2014; 86: 127–134.

Rituxan (rituximab) prescribing information. February 2010. Genetech. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf.

Ruxience (rituximab -pvvr) prescribing information. July 2019. Pfizer. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761103s000lbl.pdf.